Pathological Response and Tumor Immune Microenvironment Remodeling Upon Neoadjuvant ALK-TKI Treatment in ALK-Rearranged Non-Small Cell Lung Cancer
Authors:
- 23 June 2023
- journal article
- research article
- Published by Springer Nature in Targeted Oncology
- Vol. 18 (4) , 625-636
Abstract
Background Anaplastic lymphoma kinase-tyrosine kinase inhibitors (ALK-TKI; ALKi) have shown potent antitumor activity in metastatic non-small-cell lung cancer (NSCLC) with ALK rearrangement (ALK+); however, their efficacy in neoadjuvant settings has been poorly explored. Objective This retrospective study aimed to examine the clinical activity and tumor immune microenvironment (TIME) changes of neoadjuvant ALKi therapy. Methods ALK+ NSCLC patients treated with neoadjuvant ALKi at three hospitals in China between February 2018 and January 2023 were assessed. Data on clinical features and radiographic and pathological responses were collected and evaluated. Multiplex immunofluorescence was performed on pretreatment biopsy specimens and surgically resected specimens to investigate the impact of ALKi on TIME. Results A total of 12 patients with stage IIA–IIIB NSCLC who received neoadjuvant ALKi therapy were analyzed. The objective response rate was 91.7% (11/12) and the major pathological response (MPR) rate was 75.0% (9/12), with 58.3% (7/12) achieving a pathological complete response (pCR). After neoadjuvant ALKi therapy, we observed a significant increase in immune infiltration of CD8+ cells (histochemistry score [H-score]: median 10.51 vs. 24.01, p = 0.028; density: median 128.38 vs. 694.09 cells/mm2, p = 0.028; percentage: median 3.53% vs. 15.92%, p = 0.028) and CD4+ cells (density: median 275.56 vs. 651.82 cells/mm2, p = 0.028; percentage: median 5.98% vs. 10.46%, p = 0.028). Similar results were found for CD4+FOXP3+, CD8+PD1+, CD8+PD1-, CD8+GB+, and CD8+GB- cells. However, macrophages, including CD68+CD163- M1 and CD68+CD163+ M2 macrophages, showed little change after neoadjuvant ALKi therapy. Conclusion Neoadjuvant ALKi therapy achieved an encouraging MPR rate of 75% and enhanced immune infiltration, suggesting its safety and feasibility for ALK+ resectable NSCLC. This study advances our understanding of TIME changes by neoadjuvant ALKi therapy and merits further investigation.Keywords
Funding Information
- National Natural Science Foundation of China (82272908)
- Natural Science Foundation of Chongqing Municipality (CSTB2022NSCQ-MSX1110)
- Clinical Medical Research Talent Training Program of Army Medical University (2018XLC1015)
- Clinical medical technology innovation ability training program (2019CXLCA00)
- Guangdong Association of Clinical Trials (GACT) /Chinese Thoracic Oncology Group
- The Science Foundation for Outstanding Young People of the Army Medical University (40137-2780)
- The Science Fundation of Daping Hospital, Army Medical University (2019CXLCB011)
This publication has 28 references indexed in Scilit:
- Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanomaNature Medicine, 2018
- The diverse functions of the PD1 inhibitory pathwayNature Reviews Immunology, 2017
- Phase II study of biomarker-guided neoadjuvant treatment strategy for IIIA-N2 non-small cell lung cancer based on epidermal growth factor receptor mutation statusJournal of Hematology & Oncology, 2015
- Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant dataThe Lancet, 2014
- Pathologic Complete Response to Preoperative Chemotherapy Predicts Cure in Early-Stage Non–Small-Cell Lung Cancer: Combined Analysis of Two IFCT Randomized TrialsJournal of Thoracic Oncology, 2012
- Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysisThe Lancet Oncology, 2011
- Molecular Characteristics Predict Clinical Outcomes: Prospective Trial Correlating Response to the EGFR Tyrosine Kinase Inhibitor Gefitinib with the Presence of Sensitizing Mutations in the Tyrosine Binding Domain of the EGFR GeneClinical Cancer Research, 2011
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung CancerNew England Journal of Medicine, 2010
- Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient dataThe Lancet, 2010
- Granzyme B and Perforin Are Important for Regulatory T Cell-Mediated Suppression of Tumor ClearanceImmunity, 2007